Sugi Predict

Sugi Predict / Compounds / SCHEMBL17584

SCHEMBL17584

SCHEMBL17584

COC(=O)C1CCC(F)(F)CC1

nearest known ligand 0.44

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ TP53 P04637 1/20 0.44
▸ POLB P06746 1/20 0.42
▸ EPHX2 P34913 1/20 0.42
▸ SMN1; SMN2 Q16637 2/20 0.42
▸ CHRNB2 P17787 2/20 0.39
▸ CHRNA4 P43681 2/20 0.39
▸ CHRNB4 P30926 1/20 0.39
▸ CHRNA3 P32297 1/20 0.39
▸ CHRNA7 P36544 1/20 0.39
▸ GAA P10253 1/20 0.39
▸ PPM1B O75688 1/20 0.37
▸ PTPN1 P18031 1/20 0.37
▸ PPP1CC P36873 1/20 0.37
▸ RORC P51449 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ BRD4 O60885 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29988061 0.89 TP53 (0.38) TP53POLBEPHX2SMN1; SMN2CHRNB2
SCHEMBL13104069 0.88 TP53 (0.38) TP53POLBEPHX2SMN1; SMN2CHRNB2
SCHEMBL16048822 0.88 TP53 (0.38) TP53POLBEPHX2SMN1; SMN2CHRNB2
SCHEMBL10680731 0.83 TP53 (0.42) TP53POLBSMN1; SMN2CHRNB2CHRNA4
SCHEMBL28016776 0.83 TP53 (0.44) TP53POLBSMN1; SMN2CHRNB2CHRNA4
SCHEMBL16886407 0.82 TP53 (0.41) TP53POLBSMN1; SMN2CHRNB2CHRNA4
SCHEMBL16875438 0.82 TP53 (0.41) TP53POLBSMN1; SMN2CHRNB2CHRNA4
SCHEMBL16887583 0.82 TP53 (0.41) TP53POLBSMN1; SMN2CHRNB2CHRNA4
SCHEMBL16886411 0.82 TP53 (0.41) TP53POLBSMN1; SMN2CHRNB2CHRNA4
SCHEMBL20335450 0.82 EPHX2 (0.36) TP53EPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115667215-B Broad-spectrum antiviral medicine for resisting coronavirus 堪萨斯州立大学研究基金会 2026-05-19 — — CN disclosed
WO-2026090509-A1 SPIRO HETEROCYCLIC CDK2 INHIBITORS ARCHITECT THERAPEUTICS, INC. (US) 2026-04-30 — — WO disclosed
US-20250368625-A1 PIPERAZINES Grünenthal GmbH (DE) 2025-12-04 — — US disclosed
EP-4611747-A1 IMIDAZOLE COMPOUNDS AND THEIR USE AS SODIUM CHANNEL INHIBITORS Genep Inc. (US) 2025-09-10 — — EP disclosed
US-12092957-B2 Radiation-sensitive resin composition, method for forming resist pattern and compound JSR CORPORATION (JP) 2024-09-17 — — US disclosed
WO-2024097171-A1 IMIDAZOLE COMPOUNDS AND THEIR USE AS SODIUM CHANNEL INHIBITORS GENEP INC. (US) 2024-05-10 — — WO disclosed
WO-2024008722-A2 TREM2 MODULATORS MUNA THERAPEUTICS APS (DK) 2024-01-11 — — WO disclosed
CN-114981251-B Dibenzofuran derivative cathepsin K inhibitor and preparation method and medical application thereof 深圳信立泰药业股份有限公司 2023-11-21 — — CN disclosed
WO-2023009785-A1 TEAD INHIBITORS AND USES THEREOF CEDILLA THERAPEUTICS, INC. (US) 2023-02-02 — — WO disclosed
CN-115667215-A Broad-spectrum antiviral medicine for resisting coronavirus 堪萨斯州立大学研究基金会 2023-01-31 — — CN disclosed
WO-2017194452-A1 SECO MACROLIDE COMPOUNDS FIDELTA D.O.O. (HR) 2017-11-16 — — WO disclosed
WO-2017140274-A1 TRICYCLIC COMPOUND SERVING AS IMMUNOMODULATOR 正大天晴药业集团股份有限公司 2017-08-24 — — WO disclosed
WO-2016184312-A1 HYDROXYL PURINE COMPOUNDS AND USE THEREOF 南京明德新药研发股份有限公司 2016-11-24 — — WO disclosed
US-20160068482-A1 CARBAMATE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2016-03-10 — — US disclosed
WO-2014144836-A2 CARBAMATE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-09-18 — — WO disclosed
WO-2012025857-A1 CYCLOALKYL METHOXYBENZYL PHENYL PYRAN DERIVATIVES AS SODIUM DEPENDENT GLUCOSE CO TRANSPORTER (SGLT2) INHIBITORS HETERO RESEARCH FOUNDATION (IN) 2012-03-01 — — WO disclosed
US-20100292255-A1 Therapeutic Compounds and Their Use in Treating Diseases and Disorders MYRIAD PHARMACEUTICALS, INC. (US) 2010-11-18 — — US disclosed
US-20100292255-A1 Therapeutic Compounds and Their Use in Treating Diseases and Disorders MYRIAD PHARMACEUTICALS, INC. (US) 2010-11-18 — — US disclosed
WO-2009065035-A1 THERAPEUTIC COMPOUNDS AND THEIR USE IN TREATING DISEASES AND DISORDERS MYRIAD GENETICS, INC. (US) 2009-05-22 — — WO disclosed
US-4792618-A CHEMICAL INTERMEDIATE FOR POLYMERS AND PESTICIDES OCCIDENTAL CHEMICAL CORPORATION (US) 1988-12-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160068482-A1 CARBAMATE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS NAAA, FAAH, FAAH2 TP53 4822/4885POLB 2990/4885EPHX2 237/4885
US-12092957-B2 Radiation-sensitive resin composition, method for forming resist pattern and compound RER1, RFT1, RAD51 TP53 2982/4885POLB 706/4885EPHX2 1061/4885
US-20100292255-A1 Therapeutic Compounds and Their Use in Treating Diseases and Disorders VHL, CLN6, CFTR TP53 14/4885POLB 1782/4885EPHX2 1558/4885
US-20250368625-A1 PIPERAZINES SSTR4, SSTR5, SSTR2 TP53 4561/4885POLB 4101/4885EPHX2 4051/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.